Episode 79: A New Monoclonal for Alzheimer Disease

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Marwan Sabbagh, MD, FAAN. [LISTEN TIME: 21 minutes]

Marwan Sabbagh, MD, FAAN, behavioral neurologist at the Barrow Neurological Institute

Marwan Sabbagh, MD, FAAN

Episode 79 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 79, "A New Monoclonal for Alzheimer Disease," features an exclusive interview with Marwan Sabbagh, MD, FAAN, behavioral neurologist at the Barrow Neurological Institute. He joined the show to discuss the clinical trial results for lecanemab that were presented at the Clinical Trials on Alzheimer’s Disease meeting in San Francisco, the drug’s overall efficacy profile, as well safety information and the rates of ARIA, and more.

Lecanemab (Biogen/Eisai), is a humanized monoclonal antibody that eliminates toxic amyloid-ß protofibrils that is set to follow aducanumab as the next approved treatment for patients with early Alzheimer disease. The FDA is set to decide on the treatment's approval by January 6, 2023.

In the phase 3 Clarity AD study (NCT01767311), one of the supporting trials for its new drug application, lecanemab showed a statistically significant 27% reduction in the primary end point of Clinical Dementia Rating-Sum of Boxes when compared with placebo over an 18-month treatment period (P = .00005). Investigators reported an ARIA-edema rate of 12.5% for those on lecanemab compared with 1.7% for those on placebo. Symptomatic ARIA-E occurred at a rate of 2.8% in the lecanemab group and 0.0% in the placebo group.1

This episode is brought to you by the Giants of Multiple Sclerosis®. This premier neuroscience award program celebrates pioneers, innovators, and future generations of leaders for their remarkable achievements in Multiple Sclerosis. Nominations close January 31, 2023!

Nominate: neurologylive.com/Giants-of-MS

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

EPISODE BREAKDOWN

1:20

– Lecanemab's safety profile from Clarity AD

4:15

– Amyloid-related imaging abnormalities and lecanemab use

6:40

– The landscape of Alzheimer disease therapeutics

8:10

– Neurology News Minute

10:15

– What research has revealed about treatment approaches

13:00

– How clinical trials have evolved in dementia research

14:40

– The possibility of induction therapy in Alzheimer disease

16:30

– Looking ahead to the next steps in treatment development

18:00

– Progress toward treating Alzheimer disease earlier

Click here to subscribe to the Mind Moments® podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

REFERENCE
1. Irizarry M, van Dyck C, Sabbagh M, Bateman R, Cohen S. Clarity AD: A phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer disease. Presented at: CTAD Conference, November 29-Dec 2.
Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.